As a reminder, view sessions and submit your evaluation form to claim your CME credits by December 31, 2021.

CME Presentations

Multimodality Perspectives on Clinical Trial Development

Presented by: Tian Zhang, MD; Deborah R. Kaye, MD, MS; Lola Fashoyin-Aje, MD, PhD; Biren Saraiya, MD; Jose A. Karam, MD, FACS; Viraj Master, MD, PhD, FACS; Primo Nery Lara, Jr., MD; Naomi B. Haas, MD; Deb Maskens

Non-Clear Cell RCC

Presented by: Pavlos Msaouel, MD, PhD; Jodi K. Maranchie, MD, PhD; Ivan Pedrosa, MD, PhD; Ronald S. Boris, MD, MS; Saeed Hassanpour, PhD; Kun-Liang Guan, PhD; Bradley McGregor, MD

Keynote Lecture: Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms James P. Allison, PhD

Presented by: James P. Allison, PhD

Translational Cancer Insights

Presented by: Tracy L. Rose, MD, MPH; Hyung L. Kim, MD; A. Ari Hakimi, MD; Nazli Dizman, MD; Vitaly Margulis, MD; Moshe. C. Ornstein, MD, MA; Divya Bezwada

Mentoring the Next Generation Roundtable and Networking Hot Topics

Presented by: Sandy Ting Liu, MD; Brian Rini, MD; Ritesh R. Kotecha, MD; Amrita M. Mangalvedhekar, PhD; Krishnendu Pal, PhD; Sumanta Kumar Pal, MD; Bradley C. Leibovich, MD; James Brugarolas, MD, PhD; W. Kimryn Rathmell, MD, PhD; Jeff Yorio, MD; Brian Shuch, MD; Nizar M. Tannir, MD, FACP

Poster Walk

Presented by: Eric Kauffman, MD; Ritesh R. Kotecha, MD; Nizar M. Tannir, MD, FACP; Stephen H. Culp, MD

The Impact of Adjuvant IO on 1st Line Therapy

Presented by: Randy Sweis, MD; Toni Choueiri, MD; Martin H. Voss, MD; Viraj Master, MD, PhD, FACS; Brian Shuch, MD; Biren Saraiya, MD

Advocacy, Funding, and the Patient Experience

Presented by: Matthew T. Campbell, MD, MS; Kirsten L. Greene, MD; Gretchen Vaughan; Theresa J. Miller, PhD; Bruce Hill; Ryan Natzke

Andrew C. Novick Award Lecture

Presented by: Brian Lane, MD, PhD

Top Abstracts

Presented by: Darren R. Feldman, MD; Sunil Sudarshan, MD; Pedro C. Barata, MD, MSc; Sari Khaleel, MD; Charlotte Spencer, MBBS, MRCP; Nizar M. Tannir, MD, FACP; Akash Kaushik, PhD, MS

Role of Perioperative Therapy in RCC

Presented by: Ulka Nitkin Vaishampayan, MBBS; Sarah P. Psutka, MD, MSc; Christopher Weight, MD, MSc; Raquibul Hannan, MD, PhD; Mohamad Allaf, MD


WoodFire: A Memorial for Dr. Christopher G. Wood


Non-CME Sponsored Symposia

A treatment option for relapsed/refractory renal cell carcinoma after two or more prior systemic therapies (Sponsored by Aveo)


Poster Presentations

View the 2021 IKCS: North America Posters

TIP01: SWOG S1931 (PROBE): Phase III randomized trial of Immune checkpoint inhibitor (ICI) combination regimen with or without Cytoreductive Nephrectomy (CN) in Advanced Renal Cancer [NCT04510597]
Lead Author: Ulka Vaishampayan

TIP02: First-Line (1L) MK-1308A + Lenvatinib or Pembrolizumab + Belzutifan + Lenvatinib Versus Pembrolizumab + Lenvatinib for Clear Cell Renal Cell Carcinoma (ccRCC): A Randomized, Open-Label Phase 3 Study
Lead Author: Martin H. Voss

TIP03: Randomized, Open-Label, Phase 3 Study of Belzutifan Plus Lenvatinib Versus Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy
Lead Author: Robert Motzer

TIP04: Treatment of Advanced Renal Cell Carcinoma (RCC) After Progression on Systemic Therapy: Open-Label Phase 2 Study of Two Doses of the HIF-2α Inhibitor Belzutifan
Lead Author: Michael Atkins

TIP05: TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor
Lead Author: Toni K. Choueiri

TIP06: KEYNOTE-B61: An Open-Label Phase 2 Study of First-Line (1L) Pembrolizumab With Lenvatinib for Non–Clear Cell Renal Cell Carcinoma (nccRCC)
Lead Author: Chung-Han Lee

TIP07: Investigational Immune and Targeted Combination Therapies for Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC): A Phase 1b/2 Umbrella Study
Lead Author: Laurence Albiges

TIP08: Optimal Treatment by Invoking biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)
Lead Author: Yu-Wei Chen

TIP09: 89Zr-TLX250 for PET/CT Imaging of Clear Cell Kidney Cancer
Lead Author: Brian Shuch

TIP10: A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)
Lead Author: Rana R. McKay

CTR11: First-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in patients with long-term survival of ≥5 years in the CheckMate 214 trial
Lead Author: Nizar M. Tannir

CTR12: Outcomes with first-line nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) and treatment-related adverse event (TRAE) timing/management in CheckMate 9ER
Lead Author: Elizabeth R. Kessler

CTR13: A prospective randomized pilot trial of stereotactic body radiation therapy vs. radiofrequency ablation for the management of small renal masses
Lead Author: Ani Kapoor

CTR14: Characterization and Management of Adverse Reactions (ARs) in Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Lenvatinib + Pem- brolizumab (CLEAR Study)
Lead Author: Robert Motzer

CTR15: First results of 68Ga-EMP-100 PET for imaging c-MET expression in metastatic renal cell carcinoma
Lead Author: Lena Mittlmeier

N16: Anti-CAIX BBζ CAR4/8 T Cells Exhibit Superior Efficacy in a Clear Cell Renal Cell Carcinoma (ccRCC) Mouse Model
Lead Author: Yufei Wang

N17: Deconstructing the clear cell renal cell carcinoma using single nuclei multiomics
Lead Author: Michael P. Mariani

N18: Navigating multiomics in clear cell renal cell carcinoma-ccRCC: Network analyses on DNA methylation-5mC, DNA hydroxymethylation-5hmC, messenger RNA-mRNA, and microRNA-miRNA expression
Lead Author: Ze Zhang

N19: COVID-19 vaccination in patients with renal cell carcinoma receiving immune checkpoint inhibitors
Lead Author: Hannah Dzimitrowicz

N20: Radiation prior to combination-immunotherapy in patients with metastatic renal cell carcinoma (mRCC) and bone metastases
Lead Author: Hesham Yasin

N21: Adverse Events (AE) Management among Advanced Renal Cell Carcinoma (aRCC) Patients Receiving First-Line (1L) Axitinib+Checkpoint Inhibitor (CPI) Therapy
Leade Author: Yousef Zakharia

N22: Nivolumab plus cabozantinib (N+C) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: subgroup analysis of the Phase 3 CheckMate 9ER trial
Lead Author: Andrea Apolo

N23: Real-world clinical characteristics and treatment patterns of patients with advanced renal cell carcinoma treated with first-line avelumab + axitinib in the United States
Lead Author: Giovanni Zanotti

N24: Disease control rate (DCR) with tivozanib (TIVO) vs sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC
Lead Author: Sumanta K. Pal

N25: Cost per survivor (CPS) and cost per life-month (CPLM) of nivolumab plus ipilimumab (NIVO+IPI) versus pembrolizumab plus axitinib (PEMBRO+AXI) for previously untreated advanced renal cell carcinoma (aRCC)
Lead Author: Stephen Huo

N26: Gene expression profiling (GEP) of non-clear cell renal cell carcinoma (nccRCC) identifies a unique spectrum of transcriptional signatures with potential clinical relevance
Lead Author: Pedro Barata

N27: Spectral Dual-Layer Detector CT: A New Independent Prognostic Tool in Metastatic Renal Cell Carcinoma
Lead Author: Aska Drljevic-Nielsen

N28: Direct Imaging Characteristics of Myeloid Derived Suppressor Cell (MDSC) Populations in Renal Cell Carcinoma Patients (RCC) by Ethnicity – An Exploratory Analysis
Lead Author: Arnab Basu

N29: Expression of Aberrant Splice Variants are Strongly Associated with Clinical Outcome in Clear Cell RCC
Lead Author: Andrew Chang

N30: Molecular profiling of metastatic renal cell carcinoma (mRCC) treated with ipilimumab-nivolumab (ipi-nivo)
Lead Author: Tian Zhang

N31: Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma
Lead Author: Priyanka V. Chablani

N32: Assessing human kidney cancer metabolism with intraoperative isotope tracing
Lead Author: Divya Bezwada

N33: Outcomes of Cytoreductive Nephrectomy Followed by Active Surveillance in Metastatic Renal Cell CarcinomaBAP1 Suppresses Tumor Growth Via Interferon Beta and ISGF3 in Clear Cell Renal Cell Carcinoma
Lead Author: Sari Khaleel

N34: BAP1 Suppresses Tumor Growth Via Interferon Beta and ISGF3 in Clear Cell Renal Cell Carcinoma
Lead Author: Lauren Langbein

N35: Machine learning predicts BAP1/PBRM1 from digital histology in clear cell Renal Cell Carcinoma: TRACERx Renal
Lead Author: Charlotte Spencer

N36: Adverse Radiologic and Pathologic Features Impact Survival Outcomes for Small Renal Masses Followng Nephrectomy
Lead Author: Sari Kahleel

E37: Characterization of the tumor immune microenvironment in clear cell renal cell carcinoma (ccRCC): prognostic and therapeutic implications of an M0-macrophage enriched subtype
Lead Author: Mark Farha

E38: Disease Free Survival (DFS) as a Predictor of Overall Survival (OS) in Localized RCC following First Nephrectomy
Lead Author: Naomi Haas

E39: Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab plus ipilimumab (NIVO + IPI) versus sunitinib (SUN) in advanced renal cell carcinoma (aRCC)
Lead Author: Hans J. Hammers

E40: First-line nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) by prior nephrectomy status in the CheckMate 9ER trial
Lead Author: Camillo Porta

E41: A phase 3 trial of lenvatinib plus pembrolizumab (LEN+PEMBRO) versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma (aRCC): overall survival follow-up analysis (CLEAR study)
Lead Author: Toni K. Choueiri

E42: Characterizing the immune response in patients with renal cell carcinoma (RCC) following COVID-19 vaccination
Lead Author: Jasnoor Malhotra

E43: Nivolumab plus Cabozantinib in Patients with Non-Clear Cell Renal Cell Carcinoma: Results of a Phase 2 Trial
Lead Author: Chung-Han Lee

E44: Initial Management of Indeterminate Renal Masses in a Statewide Collaborative: a MUSIC-KIDNEY analysis
Lead Author: Mohit Butaney

E45: Documentation of Nephrometry Scores for cT1a Renal Masses Correlates with Avoidance of Radical Nephrectomy Across the MUSIC-KIDNEY Statewide QI Collaborative
Lead Author: Sara Perkins

E46: Building a roadmap for surveillance of renal masses: Results from MUSIC consensus panel
Lead Author: Amit Patel

LBA47: Molecular Dissection of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-Mesenchymal Transition Gene Expression Signature
Lead Author: Srinivas Nallandhighal